Trial reportNature medicine2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03205917 (A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults), which is not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States.PLoS pathogens · 2023Pooled it
- Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.Nature medicine · 2026Trial
- Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.The lancet. HIV · 2026Trial
- VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines.Science translational medicine · 2026Trial
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.Nature communications · 2026Trial
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.The Journal of infectious diseases · 2025Trial
- Trial
- Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.Journal of acquired immune deficiency syndromes (1999) · 2025Trial
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.Nature medicine · 2024Trial
- Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.PLoS medicine · 2024Trial
- Trial
- Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- HIV tri-specific killer engagers directly enhance NK cell function and safely expand NK cells in vivo.Cell reports. Medicine · 2026Article
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.Nature microbiology · 2026Article
- Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A.Molecules (Basel, Switzerland) · 2026Article
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
- In vivo production of an anti-HIV antibody in mice by non-viral gene knockin in primate hematopoietic stem and progenitor cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 7 institutions in 1 country.
Boris Julg *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4687-9626
Kathryn E Stephenson *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Kshitij Wagh *Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
Sabrina C TanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Rebecca ZashCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Stephen WalshCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0817-9370
Jessica AnselCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Diane KanjilalCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Joseph NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Victoria E K Walker-SperlingCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jasper OphelCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0040-1328
Katherine YanosickCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Lori MaxfieldCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7595-6205
Peter AbbinkCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1978-088X
Lauren PeterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2105-7503
Nicole L YatesDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Martina S WesleyDuke Human Vaccine Institute, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0002-8664-9307
Tom HassellInternational AIDS Vaccine Initiative, New York, NY, USA.
Huub C GelderblomInternational AIDS Vaccine Initiative, New York, NY, USA.ORCID http://orcid.org/0000-0003-4786-1003
Allen deCampStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bryan T MayerStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2258-5276
Alicia SatoStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Monica W GerberStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Elena E GiorgiTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
Lucio GamaVaccine Research Center, National Institute of Health, Bethesda, MD, USA.
Richard A KoupVaccine Research Center, National Institute of Health, Bethesda, MD, USA.
John R MascolaVaccine Research Center, National Institute of Health, Bethesda, MD, USA.
Ana MonczorHouston AIDS Research Team, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.
Sofia LupoHouston AIDS Research Team, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.
Charlotte-Paige RolleOrlando Immunology Center, Orlando, FL, USA.
Roberto ArduinoHouston AIDS Research Team, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.
Edwin DeJesusOrlando Immunology Center, Orlando, FL, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Bette KorberTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-2026-5757
Dan H BarouchRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. dbarouch@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-5127-4659
Beth Israel Deaconess Medical Center · USFred Hutch Cancer Center · USDuke University · USLos Alamos National Laboratory · USThe University of Texas Health Science Center at Houston · USInternational AIDS Vaccine Initiative · USOrlando Immunology Center · US
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4MConsortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2017 to 2026
$40.7MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MCombined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6MHIV/SIV Replication In VivoZIAAI005014 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$22.7MProject 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2018 to 2022
$14.0MAd26 Based Therapeutic Vaccines for HIVU01AI145801 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., JUELG, BORIS DOMINIK · 2020 to 2025
$9.0MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MSingle-Cell Analysis of the HIV/SIV ReservoirR01AI149670 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., SHALEK, ALEX K · 2020 to 2024
$4.6MImpact of the Intestinal Microbiome on HIV/SIV VaccinesR01OD024917 · OD · WASHINGTON UNIVERSITY · PI BALDRIDGE, MEGAN T, BAROUCH, DAN H. · 2017 to 2021
$4.3MNCATS NIH HHS UL1 TR001102NIAID NIH HHS K08 AI106408NIAID NIH HHS K23 AI114381NIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI129797NIAID NIH HHS R01 AI149670NIAID NIH HHS T32 AI007387NIAID NIH HHS U01 AI145801NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI126603NIAID NIH HHS UM1 AI164556NIH HHS R01 OD024917
Abstract
HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral escape, indicating that at least a triple bNAb therapy may be needed for robust suppression of viremia. We performed a two-part study consisting of a single-center, randomized, double-blind, dose-escalation, placebo-controlled first-in-human trial of the HIV-1 V2-glycan-specific antibody PGDM1400 alone or in combination with the V3-glycan-specific antibody PGT121 in 24 adults without HIV in part 1, as well as a multi-center, open-label trial of the combination of PGDM1400, PGT121 and the CD4-binding-site antibody VRC07-523LS in five viremic adults living with HIV not on antiretroviral therapy (ART) in part 2 ( NCT03205917 ). The primary endpoints were safety, tolerability and pharmacokinetics for both parts and antiviral activity among viremic adults living with HIV and not on ART for part 2 of the study. The secondary endpoints were changes in CD4
Indexed as
HIV-1HIV InfectionsHIV SeropositivityAdultAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsBroadly Neutralizing AntibodiesHIV AntibodiesHumansViremiaAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsBroadly Neutralizing AntibodiesHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03205917ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.